ABCC1 p.Gly421Ala
| Predicted by SNAP2: | A: D (75%), C: D (75%), D: D (91%), E: D (91%), F: D (91%), H: D (85%), I: D (85%), K: D (91%), L: D (85%), M: D (85%), N: D (85%), P: D (91%), Q: D (85%), R: D (91%), S: D (71%), T: D (85%), V: D (85%), W: D (91%), Y: D (91%), |
| Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Polymorphisms in transporter and phase II metaboli... Leuk Res. 2008 Jun;32(6):919-29. Epub 2008 Jan 18. Muller P, Asher N, Heled M, Cohen SB, Risch A, Rund D
Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups.
Leuk Res. 2008 Jun;32(6):919-29. Epub 2008 Jan 18., [PMID:18207572]
Abstract [show]
Drug metabolism/disposition and transporter genes may influence predisposition or prognosis of AML (acute myeloid leukemia) patients. We analyzed polymorphisms in 3 transporters and 4 drug metabolism genes in 293 Israeli individuals (112 AML patients and 181 controls). We analyzed: ABCC3 (MRP3) C-211T; ABCG2 (BCRP) C421A; CNT1 (SLC28A1) G565A and NAT1, NAT2, and GSTT1 and GSTM1 null alleles for influence on predisposition, as well as treatment response and survival. We found that the ABCC3 C-211T polymorphism and GSTM1 null genotype have adverse prognostic significance in AML. None of the other polymorphisms studied were found to influence either predisposition or prognosis in Israeli AML patients.
Comments [show]
None has been submitted yet.
No. Sentence Comment
199 For all of the polymorphisms we studied, there was no prior information concerning their distribution in Jews and Arabs. However, only for ABCG2 G421A did we find a significant difference in frequency.
X
ABCC1 p.Gly421Ala 18207572:199:145
status: NEW